Syntensor Terminal

Predict clinical trial outcomes for small molecules with >80% accuracy using simulated potency and ADMET assays combined with mechanism of action and trial design data.

Overview

Syntensor Terminal is a self-service application designed for predicting clinical trial outcomes for small molecules, delivering greater than 80% accuracy. Built for drug developers, investors, and life sciences professionals, the platform leverages AI-driven simulation and machine learning to address the two largest contributors to clinical trial failures — potency and ADMET properties — which together account for 60–70% of attrition across the industry.

The Syntensor platform works by first simulating a comprehensive suite of potency and ADMET assays for a given small molecule. These predicted chemical and biological properties are then combined with the burden of evidence for the drug's mechanism of action in the target disease, as well as trial design features, to generate a probability of progression from one clinical trial stage to the next.

Predictive Performance and Value

Predicts recent Phase II and Phase III clinical trial outcomes with 80% and 85% accuracy respectively, based on predicted chemical properties, biological features, and trial design factors.
Enables more confident go/no-go decisions by providing quantitative probability estimates for trial progression.
Generalises to novel molecules and previously unseen mechanisms of action, making it useful even when limited public domain information is available for a compound.

Key Features

Access predicted outcomes for hundreds of thousands of small molecule clinical trials within a single platform.
Search for trials using multiple parameters including stock ticker symbol, clinical trial ID, drug name, and/or sponsor organisation.
In development: Analyse historic performance for a specific mechanism of action within a given indication to benchmark and contextualise predictions.
In development: Gain explainability into the model's predictions by understanding the main reasons driving a given outcome forecast.

Syntensor Terminal is available as a self-service application, with early access offered through a beta community programme. The platform is positioned for use by pharmaceutical companies, biotech organisations, and investors seeking data-driven insights into clinical development risk.